A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02498665

A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This is a multicenter, open label, Phase 1 dose-escalation study of DSP-7888 Dosing Emulsion administered to adult patients with advanced malignancies. Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once every 7 to 14 days for 6 weeks during the Consolidation Phase, and once every 14 to 28 days until a discontinuation criterion is met during the Maintenance Phase.

Status: 
Recruiting
Study Date: 
Sun, 11/01/2015 to Wed, 11/01/2017
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Drug: DSP-7888 Dosing Emulsion Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once every 7 to 14 days for 6 weeks during the Consolidation Phase, and once every 14 to 28 days until a discontinuation criterion is met during the Maintenance Phase.